— Know what they know.
Not Investment Advice

ABT vs MDT vs SYK

161 measures in 16 categories, one definition each, computed from filings and market data.
ABT56.6
Abbott Laboratories
Healthcare · Medical - Devices
$104.88 +0.20%$181.5B mkt cap
Score DNA
MDT63.6
Medtronic Plc
Healthcare · Medical - Devices
$94.75 −0.73%$121.2B mkt cap
Score DNA
SYK73.6
Stryker Corporation
Healthcare · Medical - Devices
$294.66 +0.49%$113.0B mkt cap
Score DNA

Price, rebased to 100 three years ago

ABT   MDT   SYK   · weekly adjusted closes
100120140160Jan 24Apr 24Jul 24Oct 24Jan 25Apr 25Jul 25Oct 25Jan 26Apr 26Jul 26Oct 26MDT 145ABT 120SYK 116
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.

Smart money

8 measures
MeasureABTMDTSYK
Insider open-market buys, 180d 3 0 0
Insider $ bought, 180d $1.30M — —
Congress purchases, 180d 13 2 1
Last Congress purchase 2026-09-18 2026-09-11 2026-09-04
13F net change in holders −134 −94 −37
ETFs adding shares, 30d 1,517 567 1,328
ETFs trimming, 30d 1,197 485 980
Net ETF funds, 30d +320 +82 +348

Valuation

16 measures
MeasureABTMDTSYK
P/E (TTM) 33.5x
67th
23.2x
41st
30.3x
56th
PEG (P/E ÷ 3-yr EPS CAGR) 18.41
100th
1.60
60th
2.75
80th
Price / sales 3.9x
62nd
3.2x
48th
4.4x
72nd
Price / book 3.6x
54th
2.4x
36th
4.7x
62nd
Price / tangible book — — —
Price / free cash flow 20.8x
39th
19.8x
36th
24.0x
44th
Price / operating cash flow 18.3x
40th
15.1x
28th
20.5x
53rd
Enterprise value $208.5B
100th
$140.5B
98th
$124.5B
97th
EV / sales 4.5x
65th
3.7x
57th
4.8x
73rd
EV / EBITDA 19.0x
53rd
13.8x
42nd
18.6x
50th
EV / EBIT 26.1x
58th
19.2x
33rd
22.9x
45th
EV / free cash flow 23.9x
39th
22.9x
36th
26.5x
47th
Earnings yield 3.0%
70th
4.3%
82nd
3.3%
75th
FCF yield 4.8%
77th
5.1%
78th
4.2%
73rd
Operating cash flow yield 5.5%
72nd
6.6%
80th
4.9%
62nd
Graham number (per share) $45.32
56th
$59.83
74th
$116.22
93rd

Profitability (TTM)

12 measures
MeasureABTMDTSYK
Gross margin 56.8%
38th
66.7%
57th
65.2%
52nd
EBITDA margin 23.5%
82nd
27.1%
90th
25.9%
87th
Operating margin 17.0%
83rd
18.1%
85th
22.0%
93rd
EBIT margin 17.2%
82nd
19.5%
85th
21.1%
88th
Net margin 11.6%
80th
13.9%
85th
14.4%
87th
NOPAT margin 12.3%
73rd
14.4%
82nd
16.0%
85th
FCF margin 18.7%
88th
16.3%
80th
18.2%
83rd
Operating cash flow margin 21.3%
83rd
21.4%
87th
21.4%
85th
R&D / revenue 6.8%
34th
7.8%
39th
6.4%
31st
SG&A / revenue 28.9%
15th
32.4%
18th
34.0%
27th
Stock comp / revenue 1.5%
30th
1.3%
23rd
1.0%
15th
Effective tax rate 27.8%
90th
20.2%
19th
27.6%
88th

Returns on capital

11 measures
MeasureABTMDTSYK
ROE (on average equity) 10.7%
71st
10.7%
69th
16.5%
86th
ROA 5.6%
70th
5.7%
72nd
7.9%
80th
ROIC 7.3%
63rd
7.8%
66th
11.6%
73rd
ROCE 8.8%
70th
9.0%
72nd
13.2%
87th
Return on tangible assets 8.3%
73rd
8.0%
70th
11.6%
87th
Cash ROIC (OCF / invested capital) 12.7%
68th
11.6%
61st
15.6%
69th
Gross profitability (GP / assets) 24.2%
22nd
26.8%
33rd
35.1%
47th
ROIC, 3-yr average 10.8%
80th
6.0%
65th
8.7%
73rd
ROIC, 5-yr average 13.9%
82nd
6.7%
65th
10.0%
71st
ROE, 5-yr average 17.9%
85th
9.1%
73rd
15.1%
81st
Incremental ROIC -22.2%
33rd
90.1%
84th
328.7%
92nd

Growth

17 measures
MeasureABTMDTSYK
Revenue growth (TTM YoY) 8.1%
38th
9.8%
45th
8.5%
39th
Revenue growth (QoQ) 12.8%
70th
-0.5%
13th
9.5%
58th
Revenue CAGR, 3 yr 5.0%
23rd
6.0%
28th
9.9%
43rd
Revenue CAGR, 5 yr 3.0%
12th
3.5%
15th
9.7%
38th
Gross profit CAGR, 3 yr 9.9%
38th
6.5%
29th
13.1%
56th
Operating income CAGR, 3 yr 9.4%
40th
6.4%
32nd
12.8%
52nd
Net income growth (TTM YoY) -61.2%
8th
12.2%
58th
27.8%
62nd
Net income CAGR, 3 yr 1.7%
30th
13.1%
50th
11.2%
45th
EPS growth (TTM YoY) -61.0%
8th
12.4%
58th
27.9%
62nd
EPS CAGR, 3 yr 1.8%
25th
14.5%
50th
11.0%
35th
EPS CAGR, 5 yr -2.6%
20th
7.3%
45th
12.1%
65th
FCF growth (TTM YoY) 28.7%
57th
15.6%
47th
16.8%
50th
FCF CAGR, 3 yr 16.7%
31st
11.3%
19th
24.8%
42nd
Operating cash flow CAGR, 3 yr 9.9%
32nd
11.3%
39th
22.2%
58th
Book value CAGR, 3 yr 11.3%
67th
0.6%
37th
11.2%
63rd
Dividend CAGR, 3 yr 2.5%
50th
1.7%
25th
1.5%
12th
Sustainable growth rate 2.3%
4th
3.2%
15th
10.7%
48th

Margin history & stability

7 measures
MeasureABTMDTSYK
Gross margin, 3-yr average 53.4%
26th
65.1%
51st
62.9%
45th
Operating margin, 3-yr average 16.9%
87th
17.3%
89th
22.0%
94th
Net margin, 3-yr average 19.2%
94th
13.2%
85th
14.3%
87th
FCF margin, 3-yr average 16.1%
91st
15.9%
87th
16.1%
89th
Revenue stability (0-1) 0.69
17th
0.73
21st
0.99
92nd
Earnings stability (0-1) 0.04
6th
0.17
32nd
0.81
85th
Margin stability (0-1) 0.95
40th
0.98
89th
0.97
68th

Liquidity (latest quarter)

7 measures
MeasureABTMDTSYK
Cash & short-term investments $5.6B
98th
$8.8B
100th
$3.5B
95th
Net cash (− = net debt) −$27.0B
0th
−$19.3B
2nd
−$11.5B
5th
Working capital $6.7B
97th
$12.6B
100th
$7.7B
98th
Current ratio 1.38
8th
2.07
30th
2.16
33rd
Quick ratio 0.97
12th
2.09
45th
1.33
27th
Cash ratio (cash + ST investments / current liabilities) 0.31
22nd
0.75
43rd
0.52
30th
Defensive interval (days) 279 days
43rd
181 days
17th
236 days
27th

Leverage & solvency (latest quarter)

13 measures
MeasureABTMDTSYK
Total debt $32.6B
100th
$28.2B
98th
$14.9B
97th
Debt / equity 0.64
58th
0.56
53rd
0.62
56th
Net debt / equity 0.53
65th
0.38
58th
0.48
60th
Debt / assets 29.9%
53rd
30.2%
57th
31.2%
58th
Debt / capital 38.9%
58th
35.9%
53rd
38.4%
56th
Debt / EBITDA 2.98
58th
2.77
53rd
2.23
45th
Net debt / EBITDA 2.46
58th
1.90
47th
1.71
45th
Interest coverage (EBIT / interest) 12.6x
87th
10.1x
81st
6.6x
77th
Cash interest coverage 15.5x
90th
11.1x
83rd
6.7x
71st
Debt payback (years of OCF) 3.3 yrs
49th
3.5 yrs
51st
2.7 yrs
40th
Liabilities / assets 52.6%
57th
45.5%
45th
50.0%
53rd
IS credit model rating A+ AA- AA-
Implied credit spread (bps) 125
28th
100
22nd
100
22nd

Efficiency

11 measures
MeasureABTMDTSYK
Asset turnover 0.48
23rd
0.41
15th
0.55
37th
Fixed asset turnover 3.64
24th
— 5.77
64th
Inventory turnover 2.8
78th
— 1.7
41st
Receivables turnover 5.6
32nd
11.6
100th
6.7
62nd
Days sales outstanding 65 days
68th
32 days
0th
54 days
38th
Days inventory outstanding 129 days
22nd
— 219 days
59th
Days payables outstanding 83 days
75th
77 days
68th
63 days
57th
Cash conversion cycle (days) 112 days
20th
−54 days
3rd
210 days
48th
Capex / revenue 2.5%
29th
5.1%
69th
3.2%
45th
Capex / depreciation 0.40
21st
0.67
50th
0.66
48th
Operating expense ratio 43.8%
20th
46.9%
25th
43.1%
19th

Cash flow & earnings quality

7 measures
MeasureABTMDTSYK
Operating cash flow / net income 1.83
70th
1.54
44th
1.48
41st
FCF / net income 1.61
78th
1.17
44th
1.26
48th
FCF / operating cash flow 88.0%
83rd
76.3%
62nd
85.1%
76th
Capex / operating cash flow 12.0%
17th
23.7%
38th
14.9%
24th
Accruals ratio -4.6%
52nd
-3.0%
72nd
-3.8%
68th
Sloan accruals ratio -7.5%
25th
-2.1%
45th
1.6%
68th
Earnings quality score (0-1) 1.00
48th
1.00
48th
1.00
48th

Dividends & buybacks

9 measures
MeasureABTMDTSYK
Dividend yield 2.4%
97th
3.0%
100th
1.2%
93rd
Dividend per share (TTM) $2.52
97th
$2.86
98th
$3.52
100th
Payout ratio (dividends / net income) 78.5%
100th
69.8%
96th
35.3%
85th
Dividends / FCF 48.9%
89th
59.5%
97th
28.0%
83rd
Dividend growth (YoY) 7.7%
67th
1.5%
33rd
5.4%
56th
Buyback yield 1.0%
73rd
1.0%
72nd
0.1%
65th
Shareholder yield (dividends + buybacks) 3.4%
87th
4.0%
95th
1.3%
70th
Share count change (YoY) -0.5%
32nd
-0.2%
34th
-0.1%
36th
Buybacks, last 5 years $5.8B
100th
$4.9B
98th
$822.0M
78th

Scores & forensic checks

15 measures
MeasureABTMDTSYK
IS score 57
67th
64
80th
74
93rd
IS profitability 46
63rd
57
80th
72
95th
IS growth 28
11th
55
41st
64
59th
IS value 49
72nd
64
88th
52
77th
IS momentum 60
32nd
83
77th
90
86th
IS risk (safety) 80
52nd
65
42nd
100
62nd
IS quality 70
62nd
83
88th
87
95th
IS balance sheet 62
65th
70
72nd
63
67th
IS earnings quality 72
72nd
93
100th
78
93rd
IS cash flow 74
82nd
66
75th
70
77th
Piotroski F-score (0-9) 5
35th
9
95th
9
95th
Altman Z-score 3.0
52nd
2.9
47th
4.8
63rd
Beneish M-score −2.69
41st
−3.44
7th
−2.74
30th
Ohlson O-score −8.73
28th
−9.52
13th
−9.18
22nd
IS credit score 76
72nd
81
77th
81
78th

Per share

7 measures
MeasureABTMDTSYK
EPS, diluted (TTM) $3.11
75th
$4.07
87th
$9.66
100th
Book value per share $29.32
82nd
$39.09
88th
$62.15
95th
Tangible book per share −$0.40
28th
−$2.01
18th
−$3.49
13th
Revenue per share $26.73
73rd
$29.21
77th
$66.94
95th
FCF per share $5.00
85th
$4.77
83rd
$12.18
97th
Operating cash flow per share $5.68
78th
$6.25
83rd
$14.31
97th
Cash per share $3.21
57th
$6.86
80th
$9.01
87th

Size (TTM)

8 measures
MeasureABTMDTSYK
Market cap $181.5B
100th
$121.2B
98th
$113.0B
97th
Revenue $46.6B
100th
$37.5B
98th
$25.8B
97th
EBITDA $11.0B
100th
$10.2B
98th
$6.7B
97th
Net income $5.4B
100th
$5.2B
98th
$3.7B
97th
Free cash flow $8.7B
100th
$6.1B
98th
$4.7B
97th
Total assets $109.2B
100th
$93.3B
98th
$47.9B
97th
Shareholders' equity $51.1B
100th
$50.2B
98th
$24.0B
95th
Employees 115,000
100th
95,000
98th
56,000
95th

Price performance

9 measures
MeasureABTMDTSYK
1 day +0.2% −0.7% +0.5%
1 week +6.0% +7.1% +6.3%
1 month +2.6% +3.0% +5.5%
3 months +3.2% +14.7% −7.7%
6 months +8.3% +11.8% −14.2%
Year to date −15.1% +1.2% −15.4%
1 year −19.0% +2.7% −20.3%
3 years, cumulative +18.3% +43.4% +15.4%
5 years, cumulative −4.1% −11.2% +16.5%

Technicals

4 measures
MeasureABTMDTSYK
RSI 14 59.5 64.6 58.9
From 52-week high −20.6% −7.9% −24.9%
From 52-week low +28.0% +31.5% +10.4%
Beta 0.58 0.57 0.78
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms